Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMB220P
- Development stage
- Preclinical
- Lead developer
- ImmunoBiochem
- Modality
- Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
IMB220P is a first-in-class (FIC) degrader-antibody conjugate (DAC) being developed by ImmunoBiochem for the treatment of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. The therapeutic utilizes a degrader bioconjugate approach to target an undisclosed microglia-associated protein. By leveraging the specificity of an antibody to deliver a targeted protein degrader (TPD) payload to microglia, IMB220P aims to modulate neuroinflammation and protein aggregation pathways central to central nervous system (CNS) pathology. It is currently in the discovery and preclinical stages of development.
- Other names
- IMB220PIMB-220PIMB 220P
Beyond the preview
Go deeper on IMB220P.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMB220P.